Search
for

    Research

    5 / 171 results

    Community Join

    5 / 1000+ results

      community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA

      in Research/Science  63 upvotes 5 years ago
      The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

      community Adrogens and Covid-19

      in Treatment  7 upvotes 5 years ago
      The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 8 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community Brief update clascoterone phase 3 - Breezula

      in Research/Science  4 upvotes 2 years ago
      Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.